Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5120135 | 0.86 | PTPN1 (0.53) | PTPN1SMN1; SMN2PTPN2 | |
| SCHEMBL5116344 | 0.85 | PTPN1 (0.51) | PTPN1SMN1; SMN2PTPN2 | |
| SCHEMBL5128184 | 0.78 | PTPN1 (0.36) | PTPN1 | |
| SCHEMBL5112935 | 0.77 | PTPN1 (0.51) | PTPN1PTPN2PDE4APDE4BPDE4C | |
| SCHEMBL5129161 | 0.71 | PTPN1 (0.61) | PTPN1PTPN2 | |
| SCHEMBL5114118 | 0.71 | PTPN1 (0.43) | PTPN1SMN1; SMN2 | |
| SCHEMBL6689304 | 0.70 | PTPN1 (0.81) | PTPN1SMN1; SMN2PTPN2 | |
| SCHEMBL1732116 | 0.69 | PTPN1 (1.00) | PTPN1PTPN2 | |
| SCHEMBL2934032 | 0.68 | PTPN1 (0.70) | PTPN1PTPN2 | |
| SCHEMBL3918247 | 0.68 | PTPN1 (0.70) | PTPN1PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004325-A1 | PTP1B inhibitors | WYETH (US) | 2008-01-03 | — | — | US | claimed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20080004325-A1 | PTP1B inhibitors | WYETH (US) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004325-A1 | PTP1B inhibitors | PTPA, PTPRJ, PTPRR | PTPN1 18/4885SMN1; SMN2 4322/4885PTPN2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.